J. Goldman & CO LP Cyma Bay Therapeutics, Inc. Transaction History

J. Goldman & CO LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.63 - $24.47 $340,858 - $660,396	26,988 Added 19.42%	165,937 $3.92 Million
Q3 2023 Nov 14, 2023	BUY	$10.86 - $17.62 $1.51 Million - $2.45 Million	138,949 New	138,949 $2.07 Million
Q2 2019 Aug 14, 2019	SELL	$6.05 - $13.66 $927,452 - $2.09 Million	-153,298 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$8.16 - $13.42 $1.25 Million - $2.06 Million	153,298 New	153,298 $2.04 Million
Q4 2018 Feb 14, 2019	SELL	$6.54 - $11.74 $274,104 - $492,046	-41,912 Closed	0 $0

Q3 2018 Nov 14, 2018	SELL	$10.88 - $14.52 $740,079 - $987,679	-68,022 Reduced 61.88%	41,912 $464,000
Q2 2018 Aug 14, 2018	SELL	$10.66 - $14.38 $3.68 Million - $4.97 Million	-345,666 Reduced 75.87%	109,934 $1.48 Million
Q1 2018 May 15, 2018	SELL	$9.0 - $15.16 $930,600 - $1.57 Million	-103,400 Reduced 18.5%	455,600 $5.92 Million
Q4 2017 Feb 14, 2018	BUY	$7.67 - $9.31 $199,420 - $242,060	26,000 Added 4.88%	559,000 $5.14 Million
Q3 2017 Nov 14, 2017	BUY	$5.95 - $8.26 $3.17 Million - $4.4 Million	533,000	533,000 $4.3 Million

1.88M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.